Síndrome metabólico iatrogénico derivado del uso de antipsicóticos de segunda generación

  1. Alfonso Sevillano-Jiménez 1
  2. Lorena Carrascal-Laso 2
  3. Ana Belén Romero-Ruíz 3
  1. 1 Graduado en Enfermería. Enfermero Especialista en Enfermería de Salud Mental. Unidad de Salud Mental Comunitaria de Montilla (USMC-Montilla). Unidad de Gestión Clínica (UGC) de Salud Mental. Hospital Universitario Reina Sofía. Córdoba (España)
  2. 2 Licenciada en Medicina. Especialista en Psiquiatría. Servicio de Psiquiatría. Hospital Provincial de Zamora. Complejo Asistencial de Zamora. Zamora (España)
  3. 3 Graduada en Enfermería. UGC de Pediatría. Unidad de Hospitalización y Oncohematología Pediátrica y Trasplantes. Hospital Universitario Reina Sofía. Córdoba (España)
Zugehörigkeit anzeigen +
Zeitschrift:
Metas de enfermería

ISSN: 1138-7262

Datum der Publikation: 2022

Ausgabe: 25

Nummer: 4

Seiten: 65-78

Art: Artikel

DOI: 10.35667/METASENF.2022.25.1003081924 DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Metas de enfermería

Zusammenfassung

Objective: to provide evidence about the factors determining iatrogenic metabolic syndrome derived of the use of second-generation antipsychotics. Methods: a narrative review was conducted between January and February 2020. This entailed bibliographic searches in different databases and platforms: Pubmed, Science Direct, Google Scholar and UpToDate. The following key words were used (MeSH/DeCS): antipsychotic agents (antipsicóticos), atypical antipsychotics (antipsicóticos atípicos), metabolic syndrome (síndrome metabólico), Nursing (enfermería), side effects (efectos adversos), mental health (salud mental). Inclusion criteria: Spanish and English languages, original and full-text publications from the last five years, studies in human beings. Results: in total, 32 articles were retrieved. Evidence determined that clozapine, olanzapine and paliperidone were the main second-generation antipsychotics contributing to metabolic syndrome. It would be convenient to conduct anthropometric and biochemical monitoring: blood pressure, weight, abdominal perimeter, body mass index (BMI), glucose, HDL and triglycerides. A multimodal treatment approach is needed to prevent metabolic syndrome, as well as an improvement in healthcare education regarding healthy lifestyles, and considering homeostatic polypharmacy. Nursing plays a leading role by using assessment tools focused on pharmacovigilance, sexuality and quality of life. Conclusions: healthcare policies must be designed according to the expectations and needs of the psychiatric population, promoting healthy lifestyles and psychopharmacological care due to the high cardiovascular risk. Mental Health Nursing becomes a cornerstone for the care, prevention, coordination and community follow-up of iatrogenic metabolic syndrome.

Bibliographische Referenzen

  • Franch CM, Molina V, Franch JI. Factores determinantes del riesgo metabólico en el tratamiento con antipsicóticos atípicos. Rev Psiquiatr Salud Ment. 2016; 23(3):87-130. Doi: http://doi.org/10.1016/j.psiq.2016.08.001
  • Franch CM, Molina V, Franch JI. Síndrome metabólico y antipsicóticos atípicos. Posibilidad de predicción y control. Rev Psiquiatr Salud Ment (Barc.). 2017; 10(1):38-44. Doi: http://doi.org/10.1016/j.rpsm.2016.09.003
  • Sánchez ML, González J, Martínez MC. Control metabólico y prolactina en la enfermedad mental grave. Intervenciones enfermeras. Rev Enferm Salud Ment. 2018; 9:24-28.
  • Pringsheim T, Kelly M, Urness D, Teehan M, Ismail Z, Gardner D. Physical Health and Drug Safety in Individuals with Schizophrenia. Can J Psychiatry. 2017; 62(9):673-83. Doi: http://doi.org/10.1177/0706743717719898
  • Pina L, Díaz MC, Saiz PA, Bobes J, Corripio I, Grasa E, et al. Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (estudio SLiM): justificación, objetivos, diseño y descripción de la muestra. Rev Psiquiatr Salud Ment. 2014; 7(4):166-78. Doi: http://doi.org/10.1016/j.rpsm.2014.05.004
  • Ocando L, Roa A, León M, González R. Antipsicóticos atípicos y su papel en el desarrollo de enfermedades metabólicas. Rev Iberoam Hipert. 2018; 13(2):44-51.
  • Gurusamy J, Gandhi S, Damodharan D, Ganesan V, Palaniappan M. Exercise, diet and educational interventions for metabolic syndrome in persons with schizophrenia: A systematic review. Asian J Psychiatr. 2018; 36:73-85. Doi: http://doi.org/10.1016/j.ajp.2018.06.018
  • Severi E, Ferrara M, Tedeschini E, Vacca F, Mungai F, Amendolara R et al. Assessment of cardiovascular risk in an Italian psychiatric outpatient sample: A chart review of patients treated with second-generation antipsychotics. Int J Ment Health Nurs. 2018; 27(3):1002-8. Doi: http://doi.org/10.1111/inm.12407
  • Chee GL, Wynaden D, Heslop K. Improving metabolic monitoring rate for young people aged 35 and younger taking antipsychotic medications to treat a psychosis: A literature review. Arch Psychiatr Nurs. 2017; 31(6):624-33. Doi: http://doi.org/10.1016/j.apnu.2017.09.002
  • Sánchez V, Romero D, Abad MJ, Descalzo MA, Alonso S, Salazar J et al. Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics. Endocr Metab Immune Disord Drug Targets. 2018; 18(4):379-87. Doi: http://doi.org/10.2174/1871530317666171120151201
  • Sjo CP, Stenstrøm AD, Bojesen AB, Frølich JS, Bilenberg N. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment. J Child Adolesc Psychopharmacol. 2017; 27(10):884-91. Doi: http://doi.org/10.1089/cap.2016.0171
  • Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Saf. 2017; 40(9):771-81. Doi: http://doi.org/10.1007/s40264-017-0543-0
  • Vincenzi B, Henderson DC. Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications. En: Uptodate; Marder S, Herman R (ed.). 2019.
  • Jibson MD. Second-generation antipsychotic medications: Pharmacology, administration and side effects. En: Uptodate; Marder S, Herman R (ed.). 2019.
  • Meigs JB. The metabolic syndrome (insulin resistance syndrome or syndrome X). En: Uptodate; Nathan DM, Wolfsdorf JI (ed.). 2019.
  • Modrego MF, Gracia P, Cortina MT. Programa enfermero de control metabólico y calidad de vida en población ambulatoria con tratamiento antipsicótico. Rev Enferm Salud Ment. 2016; Suppl 1:S24-34.
  • Dikeç G, Arabaci LB, Uzunoglu GB, Mizrak SD. Metabolic Side Effects in Patients Using Atypical Antipsychotic Medications During Hospitalization. J Psychosoc Nurs Ment Health Serv. 2018; 56(4):28-37. Doi: http://doi.org/10.3928/02793695-20180108-05
  • Kioko E, Williams K, Newhouse B. Improving Metabolic Syndrome Screening on Patients on Second Generation Antipsychotic Medication. Arch Psychiatr Nurs. 2016; 30(6):671-7. Doi: http://doi.org/10.1016/j.apnu.2016.03.004
  • Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos K, Jara B. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology. Pharmacol Res. 2017; 101:74-85. Doi: http://doi.org/10.1016/j.phrs.2015.07.022
  • Orellana G, Rodríguez M, González N, Durán E. The association of schizophrenia with chronic non transmissible diseases. Rev Med Chil. 2017; 145(8):1047-53. Doi: http://doi.org/10.4067/s0034-98872017000801047
  • Jeon SW, Kim YK. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. Int J Mol Sci. 2017; 18(10). Doi: http://doi.org/10.3390/ijms18102174
  • Hammoudeh S, Ghuloum S, Mahfoud Z, Yehya A, Abdulhakam A, Al-Mujalli A, et al. The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study. BMC Psychiatry. 2018; 18(1):81. Doi: http://doi.org/10.1186/s12888-018-1662-6
  • Richards L, Batscha CL, McCarthy VL. Lifestyle and Behavioral Interventions to Reduce the Risk of Metabolic Syndrome in Community-Dwelling Adults With Serious Mental Illness: Implications for Nursing Practice. J Psychosoc Nurs Ment Health Serv. 2016; 54(1):46-55. Doi: http://doi.org/10.3928/02793695-20151109-02
  • Seow LS, Chong SA, Wang P, Shafie S, Ong HL, Subramaniam M. Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care. Compr Psychiatry. 2017; 74:196-203. Doi: http://doi.org/10.1016/j.comppsych.2017.01.017
  • Bressington D, Mui J, Tse ML, Gray R, Cheung EF, Chien WT. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study. BMC Psychiatry. 2016 Nov 18; 16(1):411. Doi: http://doi.org/10.1186/s12888-016-1121-1
  • Llorca PM, Lançon C, Hartry A, Brown TM, DiBenedetti DB, Kamat SA, et al. Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. BMC Psychiatry. 2017; 17(1):67. Doi: http://doi.org/10.1186/s12888-017-1213-6
  • Paredes RM, Quinones M, Marballi K, Gao X, Valdez C, Ahuja SS et al. Metabolomic profiling of schizophrenia patients at risk for metabolic syndrome. Int J Neuropsychopharmacol. 2019; 17(8):1139-48. Doi: http://doi.org/10.1017/S1461145714000157
  • Andrade C. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1: Magnitude and Moderators of the Problem. J Clin Psychiatry. 2016; 77(7):e844-7. Doi: http://doi.org/10.4088/JCP.16f10997
  • Andrade C. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 2: Nonpharmacological Interventions. J Clin Psychiatry. 2016; 77(8):e964-7. Doi: http://doi.org/10.4088/JCP.16f11060
  • Ronsley R, Nguyen D, Davidson J, Panagiotopoulos C. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. Can J Psychiatry. 2018; 60(10):441-50. Doi: http://doi.org/10.1177/070674371506001005
  • Andrade C. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 3: Psychopharmacological Interventions. J Clin Psychiatry. 2016;77(9): e1090-e1094. Doi: http://doi.org/10.4088/JCP.16f11128
  • Alswat KA, Alnemari AK, Alghamdi I, Almalki AA, Al-Thomali B, Mahfouz T. Prevalence of Metabolic Syndrome in the Hospitalized Psychiatric Patients. Med Arch. 2017; 71(6):412-6. Doi: http://doi.org/10.5455/medarh.2017.71.412-416
Fuente de los datos: Dialnet